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Purpose: Calcific aortic valve disease (CAVD) affects 2% to 6% of pop-
ulation over 65 years in industrialized countries. CAVD, assimilated to an
"atherosclerosis-like" disease, results from dysregulated mechanisms such as
fibrosis, inflammation and calcification. These mechanisms could be enhanced
by the osteoblastic differentiation of the valvular interstitial cells (VIC), the
most prevalent cell type in the human aortic valves. Leptin, known as the
product of obesity gene, has recently been linked to aortic valve calcification
in ApoE -/- mice. Our hypothesis is that leptin could play an important role in
the calcifying processes implicated in CAVD via direct effects on VIC pheno-
type in humans.
Methods: Expression of leptin and its receptor was analysed by RT-qPCR,
immunohistochemistry and ELISA in 74 human calcific aortic valves and in
10 normal valves. VIC isolated from calcific and normal aortic valves were
also analysed. The effects of leptin on the expression of osteoblastic markers
such as osteopontin, osteonectin, alkaline phosphatase, BMP-2 and BMP-7 in
cultured VIC were investigated.
Results: The presence of leptin and its long, functional, receptor isoform
(ObR-L) was observed in human aortic valves with an overexpression of
leptin in calcified vs non-calcified valvular zones (114.52 pg/mg (47.96-
234.55) vs 66.95 pg/mg (42.76-137.15), p<0.05). Moreover, ObR-L and leptin
were constitutively expressed in VIC with a higher ObR-L expression in VIC
isolated from pathological vs normal valves (p<0.05). Finally, stimulation of
VIC by leptin at physiological concentrations (20 to 100 ng/mL) significantly
increased osteonectin (pro-calcifying) and decreased BMP-7 (anti-calcifying)
expression levels.
Conclusion: Taken together, these novel findings suggest that leptin could
be involved in the process of human valve calcification by modifying VIC
phenotype.
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Chronic use of 5-HT2B receptor (5-HT2B-R) agonists (anorectic drugs or ergot
derivatives) has been associated with left cardiac valve injury but the mecha-
nisms are unclear. Lesions are characterised by increased thickness and cellu-
larity with massive extracellular matrix production. This work was designed to
study contribution of 5-HT2B and 5-HT2A-R and the link with their activation and
endothelial nitric oxide in valve degeneration. We validated an experimental
mouse model of valvulopathy by infusing (28 days; Alzet® pumps) the selective
5-HT2B-R agonist (nordexfenfluramine: NdF 1mg/kg/day) and designed
13 groups: 5 groups of WT mice (129svPas; 12 weeks): 1) control (C); 2) NdF;
3) NdF+ritanserine (2mg/kg/day); 4) NdF+SB206553 (1mg/kg/day); 5) NdF+L-
NAME (300mg/kg/day); 8 groups of transgenics: 6) 5-HT2B-/--C; 7) 5-HT2B-/--
NdF; 8) 5-HT2A/2B-/--C; 9) 5-HT2A/2B-/--NdF; 10) 5-HT2A-/--C and 11) 5-HT2A-/--
NdF and 2 groups of eNOS-/- mice 12) eNOS-/--C and 13) eNOS-/--NdF. Mice
were monitored for hemodynamic and echocardiographic parameters. At day 28,
blood 5-HT and urinary 5-HIAA concentrations were measured and hearts har-
vested for histological analysis. In controls, this analysis reveals mitral valve
lesions with increased thickness (WT-C 35±4μm vs WT-NdF 69±9μm; p<0,05)
and number of endothelial cells (+40%). Lesions are fully prevented by pharma-
cological and constitutive inactivation of: 5-HT2B-R (SB 206553 or 5-HT2B-/-
mice) and both 5-HT2A and 5-HT2B-R (ritanserine or 5-HT2A/2B-/-). In 5-HT2A-/-
treated with NdF, we still observe an increased valve thickness (5-HT2A-/--C
45±4μm vs 5-HT2A-/--NdF 60±8μm) mainly due to increased cellularity. Finally,
eNOS inhibition (L-NAME or eNOS-/- mice) also prevents lesions indicating the
crucial role of endothelial cells in 5-HT2B-mediated mitral valve degeneration. 
We demonstrate for the first time that both 5-HT2B and 5-HT2A-Rs are
involved in drug-induced valvulopathy and the role of endothelial cells and
eNOS activation.
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Heart valve diseases affect 3% of world population, and surgery is often
the only therapeutic mean. A genetic study performed on a family in which
several members exhibited a mitral valve prolapse (MVP) identified a muta-
tion on LRRFip1 gene. LRRFip1 undergoes extensive alternative transcription
splicing giving rise to five isoforms in humans and the mutation we identified
results in R94G substitution in three (Iso1, 3 and 4) out of the five isoforms.
Previous studies essentially focused on LRRFip1-Iso5 that was first described
as a transcription factor interacting with positive (Dishevelled) and negative
(Flightess-1) regulators of the canonical Wnt b-catenin dependent pathway.
LRRFip1 thus appeared as an interesting gene in MVP as it may participate
and regulate two crucial events of cardiac valve development and homeostasis
involving Wnt pathway: epithelial to mesenchymal transition and cell prolif-
eration. Interestingly, we showed using RNA sequencing analysis and RT-
PCR experiments that LRRFip1-Iso1 is the most expressed isoform in human
valves. Furthermore, LRRFip1-Iso1 has poor homology with the other iso-
forms and nothing is known about its function. We thus focused on LRRFIP1-
Iso1 and analyzed its cellular localization, its role in Wnt pathway and the
impact of R94G mutation in HEK293 cells. Cell fractionation experiments
revealed a nuclear localization of LRRFip1-Iso1 while other isoforms are
strictly cytoplasmic. We then showed by Luciferase assays and co-immuno-
precipitations that out of the five isoforms, LRRFip1-Iso1 activates the canon-
ical Wnt pathway at the highest levels and interacts mainly with Fli-1.
Furthermore, R94G mutation decreases this interaction. Thus, our studies sug-
gest that LRRFip1-Iso1 may activate the canonical Wnt pathway by opposing
Fli-1 inhibitory effects. R94G mutation may alter this key regulatory loop,
deregulate gene transcription and consequently alter valvulogenesis and/or
valve homeostasy. 
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The mitral valve prolapse (MVP) affects about 3% of the population and
remains one of the most common indications for valvular surgery. Although
the genetic basis of MVP is acknowledged since we identified FLNA
(Filamin-A; FlnA) as the first gene responsible for this life threatening dis-
ease, the genes involved and identified remain scarce. To identify new genes
and genetic variants, we performed whole exome sequencing of 20 familial
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